Pam Cohen,Sadik Kassim,Ekta Patel,Elizabeth Budde,Stephen J. Forman
申请号：
US16698358
公开号：
US20200222462A1
申请日:
2019.11.27
申请国别(地区):
US
年份:
2020
代理人:
摘要：
The present disclosure relates generally to methods treatment of hematological cancers, such as blastic plasmacytoid dendritic cell neoplasm (BPDCN), acute myeloid leukemia (AML), or Myelodysplastic Syndrome (MDS), comprising a combination of decitabine and a CD123-targeted therapy. In particular, the disclosed methods involve pretreatment of a patient with decitabine prior to administration of a CD123-targeted therapy.
